Article

Photochromic IOL to be available in Europe

Irvine, CA?Medennium Inc. expects that its photochromic IOL (Aurium) will be available in all European countries by September now that it has obtained CE mark clearance to market the lens. It is the first and only photochromic IOL, according to the company.

Irvine, CA-Medennium Inc. expects that its photochromic IOL (Aurium) will be available in all European countries by September now that it has obtained CE mark clearance to market the lens. It is the first and only photochromic IOL, according to the company.

"The idea for [the lens] is to provide additional protection for a cataract patient's retina without any compromises, such as night vision," said Stephen Zhou, PhD, vice president of research and development at Medennium.

The lens responds to changes in the environment, turning yellow when exposed to sunlight and becoming colorless indoors when no ultraviolet or blue light is present, he added.

She conducted the biocompatibility study for the lens in a rabbit model with Nick Mamalis, MD, director of the center's ophthalmic pathology laboratory.

Clinical data from two clinical sites were used to support the application for the CE mark. David Méndez, MD, director of the Instituto de la Visión, Mexicali, Mexico, implanted the lens unilaterally in 15 patients; a yellow control lens was implanted in the fellow eye. At 6 months, "all of my patients are doing very well," he said. "In addition, it appears that [eyes with the photochromic] lenses have a better best-corrected visual acuity in comparison [with eyes with] the control IOLs [implanted], especially under weak lighting conditions."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.